<?xml version='1.0' encoding='utf-8'?>
<document id="30156973"><sentence text="Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited." /><sentence text="Pharmacokinetic parameters of selective probe substrates are used to quantify the activity of an individual pharmacokinetic process (PKP) and the effect of perpetrator drugs thereon in clinical drug-drug interaction (DDI) studies" /><sentence text=" For instance, oral caffeine is used to quantify hepatic CYP1A2 activity, and oral dagibatran etexilate for intestinal P-glycoprotein (P-gp) activity"><entity charOffset="20-28" id="DDI-PubMed.30156973.s3.e0" text="caffeine" /><entity charOffset="83-103" id="DDI-PubMed.30156973.s3.e1" text="dagibatran etexilate" /><pair ddi="false" e1="DDI-PubMed.30156973.s3.e0" e2="DDI-PubMed.30156973.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30156973.s3.e0" e2="DDI-PubMed.30156973.s3.e1" /></sentence><sentence text=" However, no probe substrate depends exclusively on the PKP it is meant to quantify" /><sentence text=" Lack of selectivity for a given enzyme/transporter and expression of the respective enzyme/transporter at several sites in the human body are the main challenges" /><sentence text=" Thus, a detailed understanding of the role of individual PKPs for the pharmacokinetics of any probe substrate is essential to allocate the effect of a perpetrator drug to a specific PKP; this is a prerequisite for reliably informed pharmacokinetic models that will allow for the quantitative prediction of perpetrator effects on therapeutic drugs, also in respective patient populations not included in DDI studies" /><sentence text="" /></document>